Emerging World Pharma Inc. Strategic Partner Global Pharma OU (GPE) Meets Packaging License Regulatory Requirement

Published: Oct 25, 2011

MANASSAS, VA--(Marketwire - October 25, 2011) -

Emerging World Pharma Inc. (PINKSHEETS: EWPI) company president, Brandon Keks confirmed that the company's European strategic partner in Estonia, Global Pharma Europe OÜ (GPE), has met all regulatory requirements in Estonia to receive its packaging license and GMP. The fulfillment of these requirements is a critical step for Global Pharma Europe moving forward to obtaining its full production license. Once approved, the company will initiate its marketing strategy into the European market.


About Emerging World Pharma Inc.

Emerging World Pharma Inc. is an investor in generic based pharmaceutical companies manufacturing within developing nations. The company focuses its investments on generic pharmaceutical companies that have contracts with three major buyer groups: church, government and wholesalers. Market research shows that these branches are the most secure, protected and reputable for the distribution of medicines.

Forward Looking Statements

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Statements in this release that are forward-looking statements are based on current expectations and assumptions that are subject to known and unknown risks, uncertainties, or other factors which may cause actual results, performance, or achievements of the company to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. Actual results could differ materially because of factors such as the effect of general economic and market conditions, entry into markets with vigorous competition, market acceptance of new products and services, continued acceptance of existing products and services, technological shifts, and delays in product development and related product release schedules, any of which may cause revenues and income to fall short of anticipated levels. All information in this release is as of the date of this release. The company undertakes no duty to update any forward-looking statement to conform the statement to actual results or changes in the company's expectations.

Joel Everret
Emerging World Pharma Inc.
Investor Relations Division
Email: info@emergingpharma.com

Back to news